Side-by-side · Research reference

ChonlutenvsTestagen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED8/38 cited

BAnimal-MechanisticHUMAN-REVIEWED11/41 cited

Chonluten

Khavinson Bioregulator · Bronchial Mucosa

BronchialTarget tissue

In vitroEvidence tierAvolio 2022

THP-1Model systemAvolio 2022

Oral · Sublingual · Per Protocol

Testagen

Bioregulator Peptide · Khavinson School

Lys-Glu-Asp-GlySequenceFedoreyeva 2011

NuclearLocalizationFedoreyeva 2011

TesticularTissue target

SQ · Abdomen · Cyclical

01Mechanism of Action

Parameter

Chonluten

Testagen

Primary target

Bronchial epithelial cells and respiratory mucosa tissue complexes

Testicular tissue; proposed nuclear DNA interaction

Pathway

Bioregulatory peptide interaction → modulation of proliferative and inflammatory pathways in monocyte/macrophage populationsAvolio 2022

Nuclear penetration → DNA/oligonucleotide binding → gene expression modulation (bioregulator hypothesis)Fedoreyeva 2011

Downstream effect

Regulation of proliferative activity and inflammatory mediator production in respiratory-associated immune cellsAvolio 2022

Proposed support for spermatogenesis and testicular function; mechanistic data limited to nuclear localization and DNA interactionFedoreyeva 2011

Feedback intact?

—

Unknown — no HPG axis data

Origin

Khavinson bioregulator peptide complex derived from bronchial mucosa tissue extract methodology

Khavinson bioregulator school — isolated from testicular tissue peptide fractions

Antibody development

—

02Dosage Protocols

Parameter

Chonluten

Testagen

Typical protocol dose

10–20 mg / day

Russian bioregulator tradition dosing; not standardized in Western literature.

—

Frequency

Once or twice daily

Once daily or alternate days

Route

Oral (capsule) or sublingual

Sublingual claimed for enhanced bioavailability; not validated.

Subcutaneous

Evidence basis

In vitro mechanistic

Animal mechanistic / in vitro onlyFedoreyeva 2011

Duration

10–30 days per cycle

Traditional Khavinson protocol; cyclic administration common.

—

Clinical validation

None (PubMed indexed)

—

Typical protocol (anecdotal)

—

100–200 mcg / day

No published human dosing studies; derived from Russian bioregulator practice.

Cycle length

—

10–20 days on, 10–14 days off

Bioregulator tradition uses pulsed cycles; no controlled data.

Reconstitution

—

Sterile water or bacteriostatic saline

Half-life

—

Unknown — likely minutes (short peptide)

04Side Effects & Safety

Parameter

Chonluten

Testagen

Documented adverse events

No published safety data in PubMed-indexed literature

—

Theoretical risks

Peptide hypersensitivity, GI intolerance (uncharacterized)

—

Drug interactions

Unknown — no pharmacokinetic studies available

—

Pregnancy / lactation

No data — avoid

—

Injection site reactions

—

Erythema, mild irritation (potential)

Systemic effects

—

Unknown — no human safety data

Hormonal impact

—

No published data on testosterone, LH, FSH effects

Long-term safety

—

Unknown — no long-term studies

Absolute Contraindications

Chonluten

·Known hypersensitivity to peptide components

Testagen

·Active testicular malignancy

Relative Contraindications

Chonluten

·Pregnancy and lactation (insufficient data)
·Active malignancy (theoretical bioregulator concern)

Testagen

·Hormone-sensitive cancers (no data; theoretical caution)
·Pregnant or breastfeeding (no data)

05Administration Protocol

Parameter

Chonluten

Testagen

1. Preparation

Typically supplied as capsules or sublingual tablets. No reconstitution required. Store in cool, dry place away from light.

Add 1–2 mL sterile or bacteriostatic water to lyophilised vial. Swirl gently; do not shake. Solution should be clear.

2. Oral route

Swallow capsule with water, 20–30 minutes before meals or as directed. Traditional Khavinson protocol emphasizes empty stomach for absorption.

Subcutaneous — abdomen or thigh. Rotate sites daily. Use standard insulin syringe (27–31G).

3. Sublingual route

Place tablet under tongue, allow dissolution for 1–2 minutes. Avoid swallowing immediately. Claimed to bypass first-pass metabolism.

Morning or evening; no established optimal timing. Anecdotal preference: evening to align with circadian testosterone patterns.

4. Timing

Morning dose preferred; may split into twice-daily if higher dose used. Consistency emphasized in bioregulator protocols.

Lyophilised: room temp, dark. Reconstituted: refrigerate 2–8 °C, use within 14–21 days if bacteriostatic water used.

5. Cycle protocol

10–30 day cycles common in Russian tradition. Rest period of 1–3 months between cycles often recommended, though no published evidence for this approach.

10–20 days on, 10–14 days off. Bioregulator tradition uses pulsed exposure; rationale: prevent receptor/pathway desensitisation.